focus -WSS

focus

author：comprehensive 2025-09-04 22:14:52 - browse：2

Adam's take main illustration — Molly Ferguson/STAT

I am one week away from the launch of my weekly email newsletter! It’s called Adam’s Biotech Scorecard, and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

Do you have a biotech-related question you want me to answer in the newsletter? Send me an email at [email protected].

This week: A preview of Intra-Cellular Therapies’ Phase 3 study in major depressive disorder, and a couple of liver-disease physician perspectives on Rezdiffra, the newly approved treatment for MASH from Madrigal Pharmaceuticals.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： ARCH Venture Partners tops STAT's 2023 biotech VC rankings

WSS

Cancer cells are shown to suck energy source from immune cells

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Readout LOUD podcast: Merger Mondays, Ozempic panic

Akero's treatment for NASH falls short in cirrhosis study

Listen: Wegovy in the brain & pivotal Alzheimer's data

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

hotspot

focus

focus

Hollywood unions extend contract negotiations for actors

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

New air purifier tech could be key to improving indoor air quality

Nick Jonas talks about managing diabetes along with his career

Cancer drug shortages should be causing more outrage

STAT Virtual Event: The State of Biosimilars: What to Watch

Malaria cases in Florida and Texas: Here’s what you need to know

FDA approves RSV monoclonal antibody for infants, toddlers

Drug repurposing or repositioning? The language matters

There’s no way to know how good AI health technologies are

leisure time

A public scorecard can help hold safety

Humana CEO Bruce Broussard to step down in 2024

As digital health tech proliferates, a new institute aims to cut through hype

Akero's treatment for NASH falls short in cirrhosis study

There’s no way to know how good AI health technologies are

Massive project maps cells in human brain in unprecedented detail

knowledge

hotspot

explore

focus